facebook twitter linkedin

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries with offices in Greater Boston Area and San Francisco Bay Area, US, as well as Cambridge, UK and Krakow, Poland. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

Currently Selvita employs over 330 scientists, including 100 PhDs, with extensive experience in several areas of life sciences, and offers the following types of projects:

  • Contract chemistry services: medicinal chemistry, custom organic synthesis, scale-up and process chemistry, as well as industrial chemistry
  • Biology services: cell and molecular biology, ADME and pharmacokinetics, proteomic analyses, analytical chemistry and method validation
  • Comparative studies of biosimilar products
  • Integrated drug discovery projects combining variety of drug discovery processes from in silico drug design, and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro development, all tailored to the customer’s needs.

Selvita's laboratories possess the GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe.

Selvita also develops proprietary research programs primarily in the area of oncology. Company currently has several projects at an early or late discovery stage and is expected to move its first candidates to the clinic in 2016.

Selvita is listed on the Main Market of Warsaw Stock Exchange (WSE:SLV).